Ozempic vs Trulicity: Two Weekly Diabetes Injections
Ozempic (semaglutide, Novo Nordisk) vs Trulicity (dulaglutide, Eli Lilly)
Last verified November 2026
The verdict
Both are weekly GLP-1s for type 2 diabetes, and Ozempic is the stronger on both endpoints people ask about: −6.5 kg against Trulicity's −3.0 kg, and MACE −26% in SUSTAIN-6 against −12% in REWIND. One caveat cuts the other way. REWIND enrolled a majority who had not yet had a cardiovascular event, which is a harder population in which to show benefit. List prices are close, about $1,028 for Ozempic and $1,007 for Trulicity, with savings cards limited to commercial insurance. Both also sell direct for cash: Ozempic at $349–$499 through NovoCare and Trulicity at $389 through LillyDirect.
Side-by-side comparison
| Field | Ozempic | Trulicity |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| A1C reduction (SUSTAIN-7 head-to-head, 40 wk) | -1.8% (Ozempic 1 mg) | -1.4% (Trulicity 1.5 mg) |
| Weight loss (SUSTAIN-7 head-to-head, 40 wk) | -6.5 kg (Ozempic 1 mg) | -3.0 kg (Trulicity 1.5 mg) |
| FDA-approved indication | Type 2 diabetes; CV risk reduction in T2D + established CVD (adults only) | Type 2 diabetes (adults + pediatric ≥10); CV risk reduction in T2D ± CVD |
| Cardiovascular outcome trial | SUSTAIN-6: MACE -26% (HR 0.74, n=3,297, secondary-prevention bent) | REWIND: MACE -12% (HR 0.88, n=9,901, primary-prevention majority) |
| Evidence in advanced kidney disease | No dedicated trial at this stage of kidney disease | AWARD-7 matched insulin on blood sugar in stage 3-4 disease, with less loss of kidney function |
| The dose ladder | Weekly, climbing 0.25 to 0.5 to 1 to 2 mg | Weekly, climbing 0.75 to 1.5 to 3 to 4.5 mg |
| What it costs if you pay cash | $349–$499/mo via NovoCare self-pay ($499 at 2 mg); the savings card needs commercial insurance and a diabetes diagnosis | $389/mo via LillyDirect self-pay at every strength (list about $1,007); a $25 savings card, commercial insurance only |
What each one costs in the compounded market
Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.
Ozempic — semaglutide
from $47 /mo
463 sellers publish a standing price. This is the lowest of all 463; the median is $174 a month.
Where to get semaglutide — a selection of sellers, not a price ranking
- Embody review$79/mo
- SnagRx review$99/mo
- Collective review$59/mo + membership
Trulicity — dulaglutide
No seller on this register publishes a compounded price for it. For a drug still in trials that is expected — and anyone selling it anyway is doing so outside the system this register covers.
⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.
Frequently asked questions
Which works better for weight loss, Ozempic or Trulicity?
On the trial evidence, Ozempic. Ozempic recorded -6.5 kg (Ozempic 1 mg) and Trulicity -3.0 kg (Trulicity 1.5 mg), and the head-to-head comparison put Ozempic at -1.8% (Ozempic 1 mg) against Trulicity at -1.4% (Trulicity 1.5 mg). A head-to-head is the strongest form of this evidence because both arms run under one protocol — separate trials are not directly comparable however alike they look.
Are Ozempic and Trulicity the same drug?
No. Ozempic is semaglutide and Trulicity is dulaglutide — different molecules, and they work differently: GLP-1 receptor agonist against GLP-1 receptor agonist. Results with one do not predict results with the other.
Is Ozempic or Trulicity cheaper?
On the manufacturers' own cash pricing: Ozempic at $349–$499/mo via NovoCare self-pay ($499 at 2 mg); the savings card needs commercial insurance and a diabetes diagnosis, Trulicity at $389/mo via LillyDirect self-pay at every strength (list about $1,007); a $25 savings card, commercial insurance only. That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.
Does either one have better cardiovascular evidence?
Ozempic does. Ozempic: SUSTAIN-6: MACE -26% (HR 0.74, n=3,297, secondary-prevention bent). Trulicity: REWIND: MACE -12% (HR 0.88, n=9,901, primary-prevention majority). This matters more than it first appears — a drug with a completed outcomes trial has evidence about events that matter, not only about weight, and that is often what decides coverage.
What does a compounded version of each actually cost?
Across the 734 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide from $47 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.
Can I switch from Ozempic to Trulicity?
Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.
Which one should I ask for?
That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.
References
- 1.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016. PMID: 27633186.
- 2.Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018. PMID: 29397376.
- 3.Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. PMID: 31189511.
- 4.Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018. PMID: 29910024.
- 5.Novo Nordisk. OZEMPIC (semaglutide) injection — Prescribing Information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- 6.Eli Lilly and Company. TRULICITY (dulaglutide) injection — Prescribing Information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
Related comparisons
- Trulicity vs Wegovy
- Wegovy vs Ozempic
- Trulicity vs Mounjaro
- Rybelsus vs Trulicity
- Saxenda vs Ozempic
- Foundayo vs Trulicity
See the full drug-vs-drug verdict index or provider rankings.